Diane Bouvry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Diane Bouvry has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Arthur Mageau
IAME, UMR 1137 INSERM, Team Descid Université Paris Cité and Université Sorbonne Paris Nord, Paris, France
2 shared publications - Bruno Crestani
Service de Pneumologie, Allergologie et Transplantation, AP-HP, Hôpital Bichat Claude Bernard, Paris, France
2 shared publications - Caroline Kannengiesser
Université Paris Cité, UMR Inserm 1149, CRI, Paris, France
2 shared publications - Ibrahima Ba
Assistance Publique des Hôpitaux de Paris, Hôpital Bichat, Service de Génétique, Université Paris Diderot, Paris, France
2 shared publications - Lidwine Wemeau
Service de Pneumologie et Immuno-Allergologie, Centre de référence constitutif des maladies pulmonaires rares (site constitutif), CHU de Lille, Lille, France
2 shared publications - Marie-Pierre Debray
Service de radiologie, hôpital Bichat Claude-Bernard, AP-HP, 46, rue Henry-Huchard, 75018 Paris, France; Centre de recherche de l'inflammation (CRI), université Paris Cité, 75018 Paris, France
2 shared publications
Latest Publications
- Open Access
- 26 March 2025
- Published by Wiley in Respirology
- Vol. 30 (6) , 523-532
Impact of A Multidisciplinary Team Discussion for Genetic Lung Fibrosis
Background and Objective: Approximately 30% of individuals diagnosed with familial pulmonary fibrosis (FPF) exhibit a pathogenic variant upon genetic analysis. We established a genetic Multidisciplinary Discussion (geneMDD) aimed to enhance expertise in diagnosing and managing FPF. This study aimed at prospectively evaluating the impact of geneMDD on diagnosis and treatment in patients referred to geneMDD.Methods: In this prospective study, we enrolled all consecutive patients referred to the geneMDD. At each meeting, the impact of the meeting was questioned on the genetic conclusion, the pulmonary diagnosis, and the treatment.Results: A total of 115 patients were included. Before geneMDD, rare variants were detected in 82 out of 107 patients, among which 65 variants were classified as pathogenic/likely pathogenic. Following geneMDD, 2 pathogenic variants (3%) were reclassified as variants of uncertain significance (VUS) (n = 1) or benign (n = 1). Among the 17 variants initially classified as VUS, 2 (11.8%) were reclassified as likely pathogenic/pathogenic. The pulmonary diagnosis was confirmed for all patients (unclassifiable lung fibrosis was the more frequent diagnosis, n = 38, 33.0%). The therapeutic regimen was changed after geneMDD in 30 patients. Factors associated with therapeutic changes included the pulmonary diagnosis and presence of a pathogenic/likely pathogenic variant. In addition, the French health system allows offering whole genome sequencing (WGS) in patients with a first negative genetic analysis by NGS panel after discussion in geneMDD, but in total, since September 1st, 2021, WGS was negative for the four analysed families.Conclusion: This study suggests that geneMDD could influence the treatment of FPF patients.
- 26 March 2025
- Published by Wiley in Respirology
- Vol. 30 (6) , 523-532
Open AccessImpact of A Multidisciplinary Team Discussion for Genetic Lung Fibrosis
Background and Objective: Approximately 30% of individuals diagnosed with familial pulmonary fibrosis (FPF) exhibit a pathogenic variant upon genetic analysis. We established a genetic Multidisciplinary Discussion (geneMDD) aimed to enhance expertise in diagnosing and managing FPF. This study aimed at prospectively evaluating the impact of geneMDD on diagnosis and treatment in patients referred to geneMDD.Methods: In this prospective study, we enrolled all consecutive patients referred to the geneMDD. At each meeting, the impact of the meeting was questioned on the genetic conclusion, the pulmonary diagnosis, and the treatment.Results: A total of 115 patients were included. Before geneMDD, rare variants were detected in 82 out of 107 patients, among which 65 variants were classified as pathogenic/likely pathogenic. Following geneMDD, 2 pathogenic variants (3%) were reclassified as variants of uncertain significance (VUS) (n = 1) or benign (n = 1). Among the 17 variants initially classified as VUS, 2 (11.8%) were reclassified as likely pathogenic/pathogenic. The pulmonary diagnosis was confirmed for all patients (unclassifiable lung fibrosis was the more frequent diagnosis, n = 38, 33.0%). The therapeutic regimen was changed after geneMDD in 30 patients. Factors associated with therapeutic changes included the pulmonary diagnosis and presence of a pathogenic/likely pathogenic variant. In addition, the French health system allows offering whole genome sequencing (WGS) in patients with a first negative genetic analysis by NGS panel after discussion in geneMDD, but in total, since September 1st, 2021, WGS was negative for the four analysed families.Conclusion: This study suggests that geneMDD could influence the treatment of FPF patients.
- Open Access
- 4 April 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 63 (5) , 2301809
High risk of lung cancer in surfactant-related gene variant carriers
Background: Several rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be associated with lung cancer, but data are missing. We aimed to study the epidemiology and phenotype of lung cancer in an international cohort of SRG variant carriers.Methods: We conducted a cross-sectional study of all adults with SRG variants in the OrphaLung network and compared lung cancer risk with telomere-related gene (TRG) variant carriers.Results: We identified 99 SRG adult variant carriers (SFTPA1(n=18),SFTPA2(n=31),SFTPC(n=24),ABCA3(n=14) andNKX2-1(n=12)), including 20 (20.2%) with lung cancer (SFTPA1(n=7),SFTPA2(n=8),SFTPC(n=3),NKX2-1(n=2) andABCA3(n=0)). Among SRG variant carriers, the odds of lung cancer was associated with age (OR 1.04, 95% CI 1.01–1.08), smoking (OR 20.7, 95% CI 6.60–76.2) andSFTPA1/SFTPA2variants (OR 3.97, 95% CI 1.39–13.2). Adenocarcinoma was the only histological type reported, with programmed death ligand-1 expression ≥1% in tumour cells in three samples. Cancer staging was localised (I/II) in eight (40%) individuals, locally advanced (III) in two (10%) and metastatic (IV) in 10 (50%). We found no somatic variant eligible for targeted therapy. Seven cancers were surgically removed, 10 received systemic therapy, and three received the best supportive care according to their stage and performance status. The median overall survival was 24 months, with stage I/II cancers showing better survival. We identified 233 TRG variant carriers. The comparative risk (subdistribution hazard ratio) for lung cancer in SRG patientsversusTRG patients was 18.1 (95% CI 7.1–44.7).Conclusions: The high risk of lung cancer among SRG variant carriers suggests specific screening and diagnostic and therapeutic challenges. The benefit of regular computed tomography scan follow-up should be evaluated.
- 4 April 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 63 (5) , 2301809
Open AccessHigh risk of lung cancer in surfactant-related gene variant carriers
Background: Several rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be associated with lung cancer, but data are missing. We aimed to study the epidemiology and phenotype of lung cancer in an international cohort of SRG variant carriers.Methods: We conducted a cross-sectional study of all adults with SRG variants in the OrphaLung network and compared lung cancer risk with telomere-related gene (TRG) variant carriers.Results: We identified 99 SRG adult variant carriers (SFTPA1(n=18),SFTPA2(n=31),SFTPC(n=24),ABCA3(n=14) andNKX2-1(n=12)), including 20 (20.2%) with lung cancer (SFTPA1(n=7),SFTPA2(n=8),SFTPC(n=3),NKX2-1(n=2) andABCA3(n=0)). Among SRG variant carriers, the odds of lung cancer was associated with age (OR 1.04, 95% CI 1.01–1.08), smoking (OR 20.7, 95% CI 6.60–76.2) andSFTPA1/SFTPA2variants (OR 3.97, 95% CI 1.39–13.2). Adenocarcinoma was the only histological type reported, with programmed death ligand-1 expression ≥1% in tumour cells in three samples. Cancer staging was localised (I/II) in eight (40%) individuals, locally advanced (III) in two (10%) and metastatic (IV) in 10 (50%). We found no somatic variant eligible for targeted therapy. Seven cancers were surgically removed, 10 received systemic therapy, and three received the best supportive care according to their stage and performance status. The median overall survival was 24 months, with stage I/II cancers showing better survival. We identified 233 TRG variant carriers. The comparative risk (subdistribution hazard ratio) for lung cancer in SRG patientsversusTRG patients was 18.1 (95% CI 7.1–44.7).Conclusions: The high risk of lung cancer among SRG variant carriers suggests specific screening and diagnostic and therapeutic challenges. The benefit of regular computed tomography scan follow-up should be evaluated.
- 28 August 2023
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 15 (1) , 1S69-1S73
Pneumopathies interstitielles diffuses fibrosantes : perspectives diagnostiques et thérapeutiques
- 28 August 2023
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 15 (1) , 1S69-1S73
Pneumopathies interstitielles diffuses fibrosantes : perspectives diagnostiques et thérapeutiques
- 1 January 2019
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 36 (1) , 22-30
Tuberculose pulmonaire : évolution radiologique des lésions broncho-pulmonaires en fin de traitement
- 1 January 2019
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 36 (1) , 22-30
Tuberculose pulmonaire : évolution radiologique des lésions broncho-pulmonaires en fin de traitement
- 1 September 2015
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 7 (3) , 256-262
Fibrose pulmonaire idiopathique: nintedanib, pirfénidone, résultats complémentaires des essais cliniques
- 1 September 2015
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 7 (3) , 256-262
Fibrose pulmonaire idiopathique: nintedanib, pirfénidone, résultats complémentaires des essais cliniques